AAIC – speculative Alzheimer’s groups fail to catch the Aduhelm wave
Alector, Cassava and Annovis play up mixed data in dementia, but the markets aren’t buying it.
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
Covid-19 booster shots take centre stage
Astra and Pfizer make the case for next-generation booster vaccines, which for the UK group at least could have important financial implications.
Company Events
Lilly’s lebrikizumab looks to outdo Dupixent
Lilly will soon discover whether its purchase of Dermira was wise.
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Interviews
EQRX vows to slash drug prices where others have failed
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
Mitsubishi's Medicago readies for the second wave
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
The future of renal denervation
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.